Open Payments

YALE-NEW HAVEN HOSPITAL

Type
Teaching hospital
Where
NEW HAVEN, CT
Medicare CCN
070022
Received
$1,917,841 in 223 records, 2019 ($273,242 general, $1,644,598 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2019General payment53$273,242
2019Research payment170$1,644,598

By company

CompanyRecordsAmountYears
SEAGEN INC.68$658,2922019
Diagnostica Stago, Inc1$233,0632019
TESARO, Inc.25$151,6852019
Siemens Medical Solutions USA, Inc.7$106,6042019
Cepheid3$100,7542019
Conformis, Inc.5$87,0382019
PROGENICS PHARMACEUTICALS, INC.4$79,5932019
Lilly USA, LLC3$67,5002019
AngioDynamics, Inc.1$60,0002019
C. R. Bard, Inc. & Subsidiaries3$52,8092019
Genentech USA, Inc.1$35,0002019
Bracco Diagnostics Inc.6$34,0222019
Mallinckrodt Enterprises LLC9$33,3432019
Agios Pharmaceuticals, Inc.1$27,8722019
HOLOGIC INC3$18,7252019
Intuitive Surgical, Inc.5$16,8292019
E.R. Squibb & Sons, L.L.C.3$16,6002019
Bolton Medical Inc3$14,0902019
PTC Therapeutics, Inc.6$14,0002019
Medartis Inc.1$13,6422019
Celgene Corporation1$10,0002019
Boehringer Ingelheim Pharmaceuticals, Inc.1$9,0432019
Cardiovascular Systems Inc.11$8,5032019
Stryker Corporation17$8,2652019
Philips North America LLC2$7,4002019
Bard Peripheral Vascular, Inc.4$6,5702019
Medical Device Business Services, Inc.4$5,1952019
AstraZeneca Pharmaceuticals LP3$5,0332019
McKesson Corporation2$5,0002019
Amgen Inc.1$5,0002019
Eisai Inc.1$5,0002019
Ipsen Biopharmaceuticals, Inc1$5,0002019
Medtronic USA, Inc.1$2,8712019
Incyte Corporation1$2,5002019
Henry Schein, Inc.1$2,5002019
Shionogi Inc1$2,0112019
PFIZER INC.3$1,8362019
Boston Scientific Corporation2$1,8092019
Boehringer Ingelheim Pharma GmbH & Co.KG1$6222019
Barco, Inc.1$6142019
Biogen, Inc.1$5882019
GE HEALTHCARE1$4802019
Heron Therapeutics, Inc.1$2502019
Cochlear Americas1$2002019
Eli Lilly and Company1$432019
Abbott Laboratories1$382019

By nature of payment

NatureRecordsAmount
Research payment170$1,644,598
Compensation for services other than consulting, including serving as faculty or as a speaker at a v21$77,506
Education3$65,000
Space rental or facility fees (teaching hospital only)6$60,000
Grant11$33,177
Gift8$32,044
Charitable Contribution4$5,513

Records

DateCompanyAmountNatureFormProductStudyYear
2019-12-31Siemens Medical Solutions USA, Inc.$77,800Research paymentCash or cash equivalentBiograph mCT Flow Device, MI - Nuclear Medicine (incl. PETNET & MIBR)WBD PET imaging motion correction and population based IP2019
2019-12-31AngioDynamics, Inc.$60,000EducationIn-kind items and servicesNanoknife Device, Oncology Surgery2019
2019-12-31Siemens Medical Solutions USA, Inc.$25,082Research paymentCash or cash equivalentSC2000 Device, US - Ultrasound SystemsStructural Heart Disease Investigation2019
2019-12-31Medartis Inc.$13,642Gift (3 payments)In-kind items and servicesAPTUS Device, ORTHO2019
2019-12-31Siemens Medical Solutions USA, Inc.$1,406Research paymentCash or cash equivalentYale2018MRIPR990Huber2019
2019-12-31Siemens Medical Solutions USA, Inc.$990Research paymentCash or cash equivalentYaleNewHavenHosp2016MRIPR1023Huber2019
2019-12-31Stryker Corporation$958GiftIn-kind items and servicesNSE - HIGH SPEED DRILLS Device, NEURO SPINE ENT2019
2019-12-31Siemens Medical Solutions USA, Inc.$531Research paymentCash or cash equivalentYaleNewHavenHosp2019IPR925TurkBrowne2019
2019-12-31Siemens Medical Solutions USA, Inc.$469Research paymentCash or cash equivalentYaleNewHavenHosp2018MRIPR1066Constable2019
2019-12-31Siemens Medical Solutions USA, Inc.$326Research paymentCash or cash equivalentYale2019MRIPR990Huber2019
2019-12-18SEAGEN INC.$1,580Research paymentCash or cash equivalentPhase 1 study of SGN-CD48A in patients with relapsed or refractory multiple myeloma2019
2019-12-18SEAGEN INC.$1,170Research paymentCash or cash equivalentPhase 1 study of SGN-CD48A in patients with relapsed or refractory multiple myeloma2019
2019-12-17Bracco Diagnostics Inc.$3,000Research paymentCash or cash equivalentPROHANCE Drug, CONTRAST MEDIAAN AUTOPSY TISSUE STUDY FOR QUANTIFICATION OF GADOLINIUM LEVELS AND HISTHOPATHOLOGICAL CHANGES FROM SUBJECTS WHO RECEIVE2019
2019-12-11SEAGEN INC.$390Research paymentCash or cash equivalentA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin ASG-22CE in Combination With Pembrolizumab andor Chemot2019
2019-12-05PTC Therapeutics, Inc.$250Research paymentCash or cash equivalentA PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY OF ATALUREN IN PATIENTS WITH NONSENSE 2019
2019-12-05PTC Therapeutics, Inc.$100Research paymentCash or cash equivalentA PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY OF ATALUREN IN PATIENTS WITH NONSENSE 2019
2019-12-03Intuitive Surgical, Inc.$15,500GiftIn-kind items and servicesDa Vinci Surgical System Device, SURGERY2019
2019-12-03Intuitive Surgical, Inc.$800GiftIn-kind items and servicesDa Vinci Surgical System Device, SURGERY2019
2019-12-03Intuitive Surgical, Inc.$495GiftIn-kind items and servicesDa Vinci Surgical System Device, SURGERY2019
2019-12-03Intuitive Surgical, Inc.$30GiftIn-kind items and servicesDa Vinci Surgical System Device, SURGERY2019
2019-12-03Intuitive Surgical, Inc.$3GiftIn-kind items and servicesDa Vinci Surgical System Device, SURGERY2019
2019-12-02Agios Pharmaceuticals, Inc.$27,872Research paymentCash or cash equivalentA PHASE 1 STUDY OF AG-636 IN THE TREATMENT OF SUBJECTS WITH ADVANCED LYMPHOMA2019
2019-12-01Barco, Inc.$614GiftIn-kind items and servicesDiagnostic Displays Device, Diagnostic Imaging2019
2019-11-25Lilly USA, LLC$60,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2019
2019-11-20SEAGEN INC.$8,006Research paymentCash or cash equivalentA single-arm, open-label, multicenter study of enfortumab vedotin ASG-22CE for treatment of patients with locally advanc2019
2019-11-19Philips North America LLC$3,500Research paymentCash or cash equivalentUS Und Device, Cardiology/Vascular DiseasesVM 4.0 ECS PATIENT FEES2019
2019-11-18SEAGEN INC.$26Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12019
2019-11-14PTC Therapeutics, Inc.$650Research paymentCash or cash equivalentA PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY OF ATALUREN IN PATIENTS WITH NONSENSE 2019
2019-11-13SEAGEN INC.$6,319Research paymentCash or cash equivalentPhase 1 study of SGN-CD48A in patients with relapsed or refractory multiple myeloma2019
2019-11-07HOLOGIC INC$13,725Research paymentCash or cash equivalentDimensions Device, Breast and Skeletal HealthIIT2019
2019-11-06SEAGEN INC.$750Research paymentCash or cash equivalentA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin ASG-22CE in Combination With Pembrolizumab andor Chemot2019
2019-11-05TESARO, Inc.$1,670Research paymentCash or cash equivalentA PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADV2019
2019-11-05TESARO, Inc.$1,595Research paymentCash or cash equivalentA PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADV2019
2019-11-05TESARO, Inc.$975Research paymentCash or cash equivalentA PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADV2019
2019-11-01Bard Peripheral Vascular, Inc.$260Research paymentCash or cash equivalentLUTONIX Device, PERIPHERAL VASCULARLUTONIX BTK TRIAL CL0005012019
2019-10-30Cardiovascular Systems Inc.$1,212Research paymentCash or cash equivalentCoronary Orbital Atherectomy System Device, Atherectomy DeviceECLIPSE2019
2019-10-23Conformis, Inc.$8,604Research paymentCash or cash equivalentiTotal CR Device, ORTHOPAEDIC KNEE IMPLANTSiTotal 12-0052019
2019-10-23SEAGEN INC.$750Research paymentCash or cash equivalentA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin ASG-22CE in Combination With Pembrolizumab andor Chemot2019
2019-10-22TESARO, Inc.$26,791Research paymentCash or cash equivalentA PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADV2019
2019-10-22TESARO, Inc.$3,900Research paymentCash or cash equivalentA PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADV2019
2019-10-22TESARO, Inc.$3,150Research paymentCash or cash equivalentA PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADV2019
2019-10-21SEAGEN INC.$36,576Research paymentCash or cash equivalentA single-arm, open-label, multicenter study of enfortumab vedotin ASG-22CE for treatment of patients with locally advanc2019
2019-10-21SEAGEN INC.$20,861Research paymentCash or cash equivalentA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin ASG-22CE in Combination With Pembrolizumab andor Chemot2019
2019-10-21SEAGEN INC.$2,158Research paymentCash or cash equivalentOpen Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors2019
2019-10-21SEAGEN INC.$1,644Research paymentCash or cash equivalentPhase 1 study of SGN-CD48A in patients with relapsed or refractory multiple myeloma2019
2019-10-18SEAGEN INC.$13,814Research paymentCash or cash equivalentPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2019
2019-10-18Mallinckrodt Enterprises LLC$500Research paymentCash or cash equivalentINOMAX Drug, CRITICAL CAREREGISTRY EVALUATING PREMATURE AND TERM-NEAR-TERM NEONATES WITH PULMONARY HYPERTENSION RECEIVING INHALED NITRIC OXIDE2019
2019-10-16SEAGEN INC.$6,253Research paymentCash or cash equivalentPhase 1 study of SGN-CD48A in patients with relapsed or refractory multiple myeloma2019
2019-10-16SEAGEN INC.$712Research paymentCash or cash equivalentOpen Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors2019
2019-10-16SEAGEN INC.$620Research paymentCash or cash equivalentOpen Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors2019
2019-10-16SEAGEN INC.$565Research paymentCash or cash equivalentOpen Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors2019
2019-10-16SEAGEN INC.$452Research paymentCash or cash equivalentOpen Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors2019
2019-10-16SEAGEN INC.$96Research paymentCash or cash equivalentOpen Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors2019
2019-10-10HOLOGIC INC$1,500Research paymentCash or cash equivalentDimensions Device, Breast and Skeletal HealthIIT2019
2019-10-09SEAGEN INC.$2,730Research paymentCash or cash equivalentA single-arm, open-label, multicenter study of enfortumab vedotin ASG-22CE for treatment of patients with locally advanc2019
2019-10-09SEAGEN INC.$1,170Research paymentCash or cash equivalentA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin ASG-22CE in Combination With Pembrolizumab andor Chemot2019
2019-10-09Stryker Corporation$1,133Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREPROCESSED DEVICE Device, HYGIA HEALTH SERVICES2019
2019-10-09Stryker Corporation$595Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREPROCESSED DEVICE Device, HYGIA HEALTH SERVICES2019
2019-10-09Stryker Corporation$58Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREPROCESSED DEVICE Device, HYGIA HEALTH SERVICES2019
2019-10-09Stryker Corporation$42Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREPROCESSED DEVICE Device, HYGIA HEALTH SERVICES2019
2019-10-08Cochlear Americas$200Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentNucleus Device, Implantable hearing solution2019
2019-10-04Mallinckrodt Enterprises LLC$5,794Research paymentCash or cash equivalentINOMAX Drug, CRITICAL CAREREGISTRY EVALUATING PREMATURE AND TERM-NEAR-TERM NEONATES WITH PULMONARY HYPERTENSION RECEIVING INHALED NITRIC OXIDE2019
2019-10-02Medical Device Business Services, Inc.$1,500GrantCash or cash equivalent2019
2019-10-01TESARO, Inc.$7,152Research paymentCash or cash equivalentA PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADV2019
2019-10-01TESARO, Inc.$3,479Research paymentCash or cash equivalentA PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADV2019
2019-09-27Amgen Inc.$5,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2019
2019-09-27PTC Therapeutics, Inc.$2,340Research paymentCash or cash equivalentA PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY OF ATALUREN IN PATIENTS WITH NONSENSE 2019
2019-09-26TESARO, Inc.$10,859Research paymentCash or cash equivalentA PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADV2019
2019-09-26TESARO, Inc.$7,923Research paymentCash or cash equivalentA PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADV2019
2019-09-26Bard Peripheral Vascular, Inc.$1,500Research paymentCash or cash equivalentCOVERA Device, PERIPHERAL VASCULARAVENEW BPV140052019
2019-09-26TESARO, Inc.$178Research paymentCash or cash equivalentA PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADV2019
2019-09-24Bracco Diagnostics Inc.$4,140Research paymentCash or cash equivalentPROHANCE Drug, CONTRAST MEDIAAN AUTOPSY TISSUE STUDY FOR QUANTIFICATION OF GADOLINIUM LEVELS AND HISTHOPATHOLOGICAL CHANGES FROM SUBJECTS WHO RECEIVE2019
2019-09-19Mallinckrodt Enterprises LLC$1,500Research paymentCash or cash equivalentINOMAX Drug, CRITICAL CAREREGISTRY EVALUATING PREMATURE AND TERM-NEAR-TERM NEONATES WITH PULMONARY HYPERTENSION RECEIVING INHALED NITRIC OXIDE2019
2019-09-19Eli Lilly and Company$43Research paymentIn-kind items and servicesA PHASE 1B OPEN-LABEL PHASE 2 RANDOMIZED, DOUBLE-BLINDED STUDY EVALUATING NAB-PACLITAXEL AND GEMCITABINE WITH OR WITHOUT2019
2019-09-18SEAGEN INC.$6,714Research paymentCash or cash equivalentA single-arm, open-label, multicenter study of enfortumab vedotin ASG-22CE for treatment of patients with locally advanc2019
2019-09-18Medical Device Business Services, Inc.$1,500GrantCash or cash equivalent2019
2019-09-10Bracco Diagnostics Inc.$5,328Research paymentCash or cash equivalentCARDIOGEN-82 Drug, CONTRAST MEDIAIMPACT OF RB82 PET ON HEALTH CARE ECONOMICS IN PATIENTS WITH ACUTE CHEST PAIN IN THE EMERGENCY DEPARTMENT.2019
2019-09-05Cardiovascular Systems Inc.$1,500Research paymentCash or cash equivalentCoronary Orbital Atherectomy System Device, Atherectomy DeviceECLIPSE2019
2019-09-05Cardiovascular Systems Inc.$37Research paymentCash or cash equivalentCoronary Orbital Atherectomy System Device, Atherectomy DeviceECLIPSE2019
2019-09-03SEAGEN INC.$2,000Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12019
2019-08-28AstraZeneca Pharmaceuticals LP$33Charitable ContributionCash or cash equivalent2019
2019-08-22Philips North America LLC$3,900Research paymentCash or cash equivalentUS Und Device, Cardiology/Vascular DiseasesVM 4.0 ECS PATIENT FEES2019
2019-08-22PTC Therapeutics, Inc.$390Research paymentCash or cash equivalentA PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY OF ATALUREN IN PATIENTS WITH NONSENSE 2019
2019-08-21SEAGEN INC.$4,836Research paymentCash or cash equivalentOpen Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors2019
2019-08-21Boston Scientific Corporation$1,500GrantCash or cash equivalentGENERAL - BRADY Device, BRADY2019
2019-08-14Conformis, Inc.$6,292Research paymentCash or cash equivalentiTotal CR Device, ORTHOPAEDIC KNEE IMPLANTSiTotal 12-0052019
2019-08-13C. R. Bard, Inc. & Subsidiaries$9,249Research paymentCash or cash equivalentARCTIC SUN Device, MEDICAL SYSTEMSINTREPID BMD11112019
2019-08-13C. R. Bard, Inc. & Subsidiaries$1,148Research paymentIn-kind items and servicesARCTIC SUN Device, MEDICAL SYSTEMSINTREPID BMD11112019
2019-08-08Ipsen Biopharmaceuticals, Inc$5,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentSOMATULINE DEPOT Drug, Oncology/Endocrinology2019
2019-08-07AstraZeneca Pharmaceuticals LP$2,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentCALQUENCE Drug, Oncology2019
2019-08-06TESARO, Inc.$390Research paymentCash or cash equivalentA PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADV2019
2019-08-01Cepheid$49,300Research paymentCash or cash equivalent2019
2019-08-01AstraZeneca Pharmaceuticals LP$2,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentLYNPARZA Drug, Oncology2019
2019-07-30GE HEALTHCARE$480Charitable ContributionCash or cash equivalent2019
2019-07-25Mallinckrodt Enterprises LLC$5,814Research paymentCash or cash equivalentINOMAX Drug, CRITICAL CAREREGISTRY EVALUATING PREMATURE AND TERM-NEAR-TERM NEONATES WITH PULMONARY HYPERTENSION RECEIVING INHALED NITRIC OXIDE2019
2019-07-25Cardiovascular Systems Inc.$249Research paymentCash or cash equivalentPeripheral Orbital Atherectomy System Device, Atherectomy DeviceLIBERTY 3602019
2019-07-22SEAGEN INC.$12,610Research paymentCash or cash equivalentPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2019
2019-07-22PFIZER INC.$400Research paymentCash or cash equivalentA PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY TOLERA2019
2019-07-16SEAGEN INC.$52,944Research paymentCash or cash equivalentA single-arm, open-label, multicenter study of enfortumab vedotin ASG-22CE for treatment of patients with locally advanc2019
2019-07-16SEAGEN INC.$16,696Research paymentCash or cash equivalentPhase 1 study of SGN-CD48A in patients with relapsed or refractory multiple myeloma2019
2019-07-16SEAGEN INC.$3,009Research paymentCash or cash equivalentA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin ASG-22CE in Combination With Pembrolizumab andor Chemot2019
2019-07-16Stryker Corporation$1,279Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREPROCESSED DEVICE Device, HYGIA HEALTH SERVICES2019
2019-07-16SEAGEN INC.$1,079Research paymentCash or cash equivalentOpen Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors2019
2019-07-16Stryker Corporation$493Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREPROCESSED DEVICE Device, HYGIA HEALTH SERVICES2019
2019-07-16Stryker Corporation$58Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREPROCESSED DEVICE Device, HYGIA HEALTH SERVICES2019
2019-07-16Stryker Corporation$57Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREPROCESSED DEVICE Device, HYGIA HEALTH SERVICES2019
2019-07-11Conformis, Inc.$26,000Research paymentCash or cash equivalentiTotal CR Device, ORTHOPAEDIC KNEE IMPLANTSiTotal 12-0052019
2019-07-11Incyte Corporation$2,500EducationCash or cash equivalent2019
2019-07-11Cardiovascular Systems Inc.$2,000Research paymentCash or cash equivalentCoronary Orbital Atherectomy System Device, Atherectomy DeviceECLIPSE2019
2019-07-10SEAGEN INC.$2,000Research paymentCash or cash equivalentA single-arm, open-label, multicenter study of enfortumab vedotin ASG-22CE for treatment of patients with locally advanc2019
2019-07-10SEAGEN INC.$1,521Research paymentCash or cash equivalentPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2019
2019-07-10SEAGEN INC.$1,500Research paymentCash or cash equivalentPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2019
2019-07-10SEAGEN INC.$750Research paymentCash or cash equivalentOpen Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors2019
2019-07-09TESARO, Inc.$10,594Research paymentCash or cash equivalentA PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADV2019
2019-07-08Biogen, Inc.$588Research paymentCash or cash equivalentA Study to Evaluate the Efficacy and Safety of BIIB093 in Participants With Brain Contusion2019
2019-07-05E.R. Squibb & Sons, L.L.C.$5,500GrantCash or cash equivalent2019
2019-07-05E.R. Squibb & Sons, L.L.C.$1,100GrantCash or cash equivalent2019
2019-07-02TESARO, Inc.$48,344Research paymentCash or cash equivalentA PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADV2019
2019-07-02TESARO, Inc.$7,281Research paymentCash or cash equivalentA PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADV2019
2019-07-02TESARO, Inc.$2,271Research paymentCash or cash equivalentA PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADV2019
2019-07-02TESARO, Inc.$1,988Research paymentCash or cash equivalentA PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADV2019
2019-07-02TESARO, Inc.$1,332Research paymentCash or cash equivalentA PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADV2019
2019-07-02TESARO, Inc.$1,052Research paymentCash or cash equivalentA PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADV2019
2019-07-02Cardiovascular Systems Inc.$37Research paymentCash or cash equivalentCoronary Orbital Atherectomy System Device, Atherectomy DeviceECLIPSE2019
2019-06-27TESARO, Inc.$2,000Research paymentCash or cash equivalentA PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADV2019
2019-06-27TESARO, Inc.$975Research paymentCash or cash equivalentA PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADV2019
2019-06-20Eisai Inc.$5,000GrantCash or cash equivalentLenvima Drug, Oncology2019
2019-06-19SEAGEN INC.$500Research paymentCash or cash equivalentPhase 1 study of SGN-CD48A in patients with relapsed or refractory multiple myeloma2019
2019-06-18Bracco Diagnostics Inc.$6,070Research paymentCash or cash equivalentPROHANCE Drug, CONTRAST MEDIAAN AUTOPSY TISSUE STUDY FOR QUANTIFICATION OF GADOLINIUM LEVELS AND HISTHOPATHOLOGICAL CHANGES FROM SUBJECTS WHO RECEIVE2019
2019-06-10Heron Therapeutics, Inc.$250Research paymentCash or cash equivalentHTX-011 DrugPhase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2)2019
2019-06-04Henry Schein, Inc.$2,500Compensation for services other than consulting, including serving as faculty or as a speaker at a vIn-kind items and services2019
2019-06-03Lilly USA, LLC$2,500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2019
2019-05-30Medical Device Business Services, Inc.$1,500GrantCash or cash equivalent2019
2019-05-28Bolton Medical Inc$10,140Research paymentCash or cash equivalentRelayPro-T IP-0018-16 Device, EndovascularRelayPro-T IP-0018-162019
2019-05-28Bolton Medical Inc$2,000Research paymentCash or cash equivalentRelayPro-T IP-0018-16 Device, EndovascularRelayPro-T IP-0018-162019
2019-05-28Bolton Medical Inc$1,950Research paymentCash or cash equivalentRelayPro-T IP-0018-16 Device, EndovascularRelayPro-T IP-0018-162019
2019-05-28Boehringer Ingelheim Pharma GmbH & Co.KG$622Research paymentIn-kind items and servicesPhase I/II monotherapy of low risk MDS2019
2019-05-23E.R. Squibb & Sons, L.L.C.$10,000GrantCash or cash equivalent2019
2019-05-23Cardiovascular Systems Inc.$3,000Research paymentCash or cash equivalentCoronary Orbital Atherectomy System Device, Atherectomy DeviceECLIPSE2019
2019-05-22Celgene Corporation$10,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2019
2019-05-20Cepheid$2,522Research paymentIn-kind items and services2019
2019-05-13McKesson Corporation$2,500Charitable ContributionCash or cash equivalent2019
2019-05-09Mallinckrodt Enterprises LLC$2,000Research paymentCash or cash equivalentINOMAX Drug, CRITICAL CAREREGISTRY EVALUATING PREMATURE AND TERM-NEAR-TERM NEONATES WITH PULMONARY HYPERTENSION RECEIVING INHALED NITRIC OXIDE2019
2019-05-08SEAGEN INC.$19,773Research paymentCash or cash equivalentPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2019
2019-05-06SEAGEN INC.$43,873Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12019
2019-05-02Cardiovascular Systems Inc.$56Research paymentCash or cash equivalentCoronary Orbital Atherectomy System Device, Atherectomy DeviceECLIPSE2019
2019-04-29HOLOGIC INC$3,500Research paymentCash or cash equivalentDimensions Device, Breast and Skeletal HealthIIT2019
2019-04-24Medtronic USA, Inc.$2,871GrantIn-kind items and services2019
2019-04-22SEAGEN INC.$17,890Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12019
2019-04-18SEAGEN INC.$108,684Research paymentCash or cash equivalentA single-arm, open-label, multicenter study of enfortumab vedotin ASG-22CE for treatment of patients with locally advanc2019
2019-04-18SEAGEN INC.$38,395Research paymentCash or cash equivalentOpen Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors2019
2019-04-18SEAGEN INC.$22,025Research paymentCash or cash equivalentA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin ASG-22CE in Combination With Pembrolizumab andor Chemot2019
2019-04-18SEAGEN INC.$15,260Research paymentCash or cash equivalentPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2019
2019-04-17Mallinckrodt Enterprises LLC$4,435Research paymentCash or cash equivalentINOMAX Drug, CRITICAL CAREREGISTRY EVALUATING PREMATURE AND TERM-NEAR-TERM NEONATES WITH PULMONARY HYPERTENSION RECEIVING INHALED NITRIC OXIDE2019
2019-04-12Stryker Corporation$1,142Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREPROCESSED DEVICE Device, HYGIA HEALTH SERVICES2019
2019-04-12Stryker Corporation$427Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREPROCESSED DEVICE Device, HYGIA HEALTH SERVICES2019
2019-04-12Stryker Corporation$64Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREPROCESSED DEVICE Device, HYGIA HEALTH SERVICES2019
2019-04-12Stryker Corporation$59Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREPROCESSED DEVICE Device, HYGIA HEALTH SERVICES2019
2019-04-11Genentech USA, Inc.$35,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentAlecensa Biological, BioOncology2019
2019-04-10SEAGEN INC.$4,500Research paymentCash or cash equivalentPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2019
2019-04-10SEAGEN INC.$2,171Research paymentCash or cash equivalentPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2019
2019-04-10SEAGEN INC.$1,170Research paymentCash or cash equivalentPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2019
2019-04-10SEAGEN INC.$750Research paymentCash or cash equivalentPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2019
2019-04-08Lilly USA, LLC$5,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2019
2019-04-04Cardiovascular Systems Inc.$50Research paymentCash or cash equivalentCoronary Orbital Atherectomy System Device, Atherectomy DeviceECLIPSE2019
2019-04-03McKesson Corporation$2,500Charitable ContributionCash or cash equivalent2019
2019-04-03SEAGEN INC.$495Research paymentCash or cash equivalentA single-arm, open-label, multicenter study of enfortumab vedotin ASG-22CE for treatment of patients with locally advanc2019
2019-04-01SEAGEN INC.$6,630Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12019
2019-04-01SEAGEN INC.$1,500Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12019
2019-04-01SEAGEN INC.$390Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12019
2019-03-31Abbott Laboratories$38Research paymentIn-kind items and servicesHeart Failure Device, Cardiac Arrhythmias and Heart FailureHemodynamic Guided Monitoring in Heart Failure (HF) Trial (GUIDE-HF)2019
2019-03-28Conformis, Inc.$13,640Research paymentCash or cash equivalentiTotal CR Device, ORTHOPAEDIC KNEE IMPLANTSiTotal 12-0052019
2019-03-27C. R. Bard, Inc. & Subsidiaries$42,412Research paymentCash or cash equivalentARCTIC SUN Device, MEDICAL SYSTEMSINTREPID BMD11112019
2019-03-27SEAGEN INC.$3,663Research paymentCash or cash equivalentA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin ASG-22CE in Combination With Pembrolizumab andor Chemot2019
2019-03-27SEAGEN INC.$3,338Research paymentCash or cash equivalentA single-arm, open-label, multicenter study of enfortumab vedotin ASG-22CE for treatment of patients with locally advanc2019
2019-03-27Bard Peripheral Vascular, Inc.$1,560Research paymentCash or cash equivalentVERNACULAR BPV140072019
2019-03-27SEAGEN INC.$780Research paymentCash or cash equivalentA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin ASG-22CE in Combination With Pembrolizumab andor Chemot2019
2019-03-21Mallinckrodt Enterprises LLC$5,391Research paymentCash or cash equivalentINOMAX Drug, CRITICAL CAREREGISTRY EVALUATING PREMATURE AND TERM-NEAR-TERM NEONATES WITH PULMONARY HYPERTENSION RECEIVING INHALED NITRIC OXIDE2019
2019-03-20Diagnostica Stago, Inc$233,063Research paymentCash or cash equivalent Device, Hemostasis2019
2019-03-20SEAGEN INC.$2,200Research paymentCash or cash equivalentPhase 1 study of SGN-CD48A in patients with relapsed or refractory multiple myeloma2019
2019-03-20SEAGEN INC.$671Research paymentCash or cash equivalentA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin ASG-22CE in Combination With Pembrolizumab andor Chemot2019
2019-03-19TESARO, Inc.$2,562Research paymentCash or cash equivalentA PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADV2019
2019-03-19TESARO, Inc.$1,052Research paymentCash or cash equivalentA PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN ANTI-TIM-3 MONOCLONAL ANTIBODY, IN PATIENTS WITH ADV2019
2019-03-14Conformis, Inc.$32,500Research paymentCash or cash equivalentiTotal CR Device, ORTHOPAEDIC KNEE IMPLANTSiTotal 12-0052019
2019-03-06SEAGEN INC.$1,500Research paymentCash or cash equivalentA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin ASG-22CE in Combination With Pembrolizumab andor Chemot2019
2019-03-04SEAGEN INC.$1,170Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12019
2019-02-27SEAGEN INC.$4,407Research paymentCash or cash equivalentPhase 1 study of SGN-CD48A in patients with relapsed or refractory multiple myeloma2019
2019-02-27SEAGEN INC.$2,500EducationCash or cash equivalentADCETRIS Biological, Oncology2019
2019-02-27SEAGEN INC.$1,300Research paymentCash or cash equivalentPhase 1 study of SGN-CD48A in patients with relapsed or refractory multiple myeloma2019
2019-02-27SEAGEN INC.$390Research paymentCash or cash equivalentPhase 1 study of SGN-CD48A in patients with relapsed or refractory multiple myeloma2019
2019-02-27SEAGEN INC.$247Research paymentCash or cash equivalentPhase 1 study of SGN-CD48A in patients with relapsed or refractory multiple myeloma2019
2019-02-25Boehringer Ingelheim Pharmaceuticals, Inc.$9,043Research paymentIn-kind items and servicesPhase I BI907828 in advance TP53WT MDM2 amplified2019
2019-02-25Medical Device Business Services, Inc.$695GrantCash or cash equivalent2019
2019-02-22PROGENICS PHARMACEUTICALS, INC.$28,340Research paymentIn-kind items and servicesStudy of 18F DCFPyL PET CT Imaging in Patients With Suspected Recurrence of Prostate Cancer CONDOR2019
2019-02-22PROGENICS PHARMACEUTICALS, INC.$12,155Research paymentIn-kind items and servicesStudy of 18F DCFPyL PET CT Imaging in Patients With Suspected Recurrence of Prostate Cancer CONDOR2019
2019-02-21Mallinckrodt Enterprises LLC$423Research paymentCash or cash equivalentINOMAX Drug, CRITICAL CAREREGISTRY EVALUATING PREMATURE AND TERM-NEAR-TERM NEONATES WITH PULMONARY HYPERTENSION RECEIVING INHALED NITRIC OXIDE2019
2019-02-19SEAGEN INC.$780Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12019
2019-02-15PROGENICS PHARMACEUTICALS, INC.$34,357Research paymentIn-kind items and servicesStudy of 18F DCFPyL PET CT Imaging in Patients With Suspected Recurrence of Prostate Cancer CONDOR2019
2019-02-15PROGENICS PHARMACEUTICALS, INC.$4,741Research paymentIn-kind items and servicesStudy of 18F DCFPyL PET CT Imaging in Patients With Suspected Recurrence of Prostate Cancer CONDOR2019
2019-02-11PFIZER INC.$103Research paymentCash or cash equivalentA PHASE 1 RANDOMIZED DOUBLEBLIND THIRDPARTY OPEN PLACEBOCONTROLLED DOSE ESCALATING STUDY TO EVALUATE THE SAFETY TOLERABI2019

The latest 200 records of 223.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

South Central Connecticut Planning RegionNew Haven city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In New Haven, CT, county South Central Connecticut Planning Region, CT, state Connecticut; placed by its city name.

MeasurePlace (city or town)
New Haven, CT
County
South Central Connecticut Planning Region, CT
State
Connecticut
Population B01003134,349570,5983,624,508
Population, 2020 census P1134,023-3,605,944
Median age B0100231.940.241.1
Under 18 B0100121.3%19.6%20.2%
65 and over B0100111.8%18.6%18.5%
Households B1100154,773230,6731,434,007
Foreign born B0500218.0%13.7%15.7%
Median household income B19013$56,851$88,197$95,781
Median family income B19113$68,668$115,384$122,706
Per capita income B19301$36,242$49,766$55,915
Poverty rate B1700123.9%11.4%10.0%
Unemployment rate B230258.4%6.0%5.6%
Civilian labor force B2302569,528307,6071,959,490
Mean commute (minutes) B0801321.523.526.5
Bachelor's degree or higher B1500338.9%42.0%42.5%
Housing units B2500160,333248,2671,541,822
Owner-occupied B2500328.4%60.5%66.5%
Renters B2500371.6%39.5%33.5%
Median home value B25077$287,100$353,100$366,900
Median gross rent B25064$1,488$1,525$1,488
White, not Hispanic B0300230.0%58.5%61.9%
Black B0300227.6%13.0%9.8%
Hispanic or Latino B0300231.0%19.5%18.3%
Asian B030025.2%4.5%4.7%
American Indian and Alaska Native B030020.2%0.1%0.1%

Economy now FRED unemployment 5.1% in Sep 2026 (4.2% a year earlier); per capita personal income $102,307 in 2025, up 33% in five years (+7.1% after inflation); Unemployment rate: 4.7% in Sep 2016 to 5.1% in Sep 2026; low 3.1%, high 11.9% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in New Haven, CT.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.